SG Americas Securities LLC Boosts Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

SG Americas Securities LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.4% in the first quarter, Holdings Channel.com reports. The fund owned 21,420 shares of the company’s stock after acquiring an additional 2,196 shares during the quarter. SG Americas Securities LLC’s holdings in IDEXX Laboratories were worth $11,565,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Patron Partners LLC boosted its holdings in IDEXX Laboratories by 2.7% during the 4th quarter. Patron Partners LLC now owns 765 shares of the company’s stock valued at $425,000 after acquiring an additional 20 shares during the period. NewEdge Wealth LLC boosted its holdings in IDEXX Laboratories by 3.1% during the 4th quarter. NewEdge Wealth LLC now owns 659 shares of the company’s stock valued at $366,000 after acquiring an additional 20 shares during the period. Manchester Capital Management LLC raised its position in IDEXX Laboratories by 11.9% during the 4th quarter. Manchester Capital Management LLC now owns 188 shares of the company’s stock valued at $104,000 after purchasing an additional 20 shares in the last quarter. BluePath Capital Management LLC raised its position in IDEXX Laboratories by 1.8% during the 4th quarter. BluePath Capital Management LLC now owns 1,197 shares of the company’s stock valued at $663,000 after purchasing an additional 21 shares in the last quarter. Finally, Valley National Advisers Inc. raised its position in IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 22 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In related news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the transaction, the director now directly owns 161 shares of the company’s stock, valued at approximately $87,068.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.11% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

IDXX has been the subject of a number of research analyst reports. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Morgan Stanley decreased their target price on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research report on Tuesday, May 14th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Barclays decreased their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $586.63.

IDEXX Laboratories Trading Up 1.0 %

IDXX opened at $492.74 on Friday. The firm has a market cap of $40.70 billion, a price-to-earnings ratio of 47.70, a PEG ratio of 4.02 and a beta of 1.32. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The stock has a fifty day moving average price of $500.41 and a 200-day moving average price of $522.09.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The firm had revenue of $964.10 million during the quarter, compared to analyst estimates of $965.43 million. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.